The SmartPak™ Pharmacy Equine Product Information Sheet

Flunixin Meglumine Injectable Solution

Common Drug Name – Flunixin meglumine

How Supplied by SmartPak- Each milliliter contains Flunixin meglumine equivalent to 50mg Flunixin. It is available in 100 ml and 250 ml multi-dose vials.

Category – Flunixin meglumine is a potent non-narcotic, nonsteroidal, analgesic agent with anti-inflammatory and antipyretic activity.

Caution - Federal law restricts this drug to use by or on the order of a licensed veterinarian. For intravenous or intramuscular use in horses and for intravenous use in beef and dairy cattle. Not for use in dry dairy cows and veal calves.

Indications (Uses) –
Horse: Flunixin meglumine injectable solution is recommended for the alleviation of inflammation and pain associated with musculoskeletal disorders in the horse. It is also recommended for the alleviation of visceral pain associated with colic in the horse.
Cattle: Flunixin meglumine injectable solution is for the control of pyrexia associated with bovine respiratory disease and endotoxemia and acute bovine mastitis. It is also for the control of inflammation in endotoxemia.

Dosage and Administration –
Horse: The recommended dose for musculoskeletal disorders is 0.5mg/lb (1ml/100lbs) of body weight once daily. Treatment may be given by intravenous or intramuscular injection and repeated for up to 5 days. Studies show onset of activity is within 2 hours. Peak response occurs between 12 and 16 hours and duration of activity is 24 – 36 hours. The recommended dose for the alleviation of pain associated with equine colic is 0.5mg/lb of body weight. Intravenous administration is recommended for prompt relief. Studies show pain is alleviated in less than 15 minutes in many cases.
Cattle: The recommended dose for control of pyrexia associated with bovine respiratory disease and endotoxemia and control of inflammation in endotoxemia is 1.1 - 2.2mg/kg (0.5 – 1mg/lb; 1 – 2 ml/100lbs) of body weight given by slow intravenous administration either once a day as a single dose or divided into two doses administered at 12-hour intervals for up to 3 days. The total daily dose should not exceed 2.2mg/kg (1mg/lb) of body weight. Avoid rapid intravenous administration of the drug. The recommended dose for acute bovine mastitis is 2.2mg/kg (1 mg/lb; 2ml/100lbs) of body weight given once by intravenous administration.

Contraindications –
Horses: There are no known contraindications to this drug when used as directed. Intra-arterial injection should be avoided. Horses inadvertently injected intra-arterially can show adverse reactions such as ataxia, incoordination, hyperventilation, hysteria and muscle weakness. Signs are transient and disappear without antidotal medication within a few minutes. Do not use in horses showing hypersensitivity to Flunixin meglumine.
Cattle: There are no known contraindications to this drug in cattle when used as directed. Do not use in animals showing hypersensitivity to Flunixin meglumine. Use judiciously when renal impairment or gastric ulceration are suspected.

Human Warning – Not for human use. Keep out of reach of children.

Warning – Cattle must not be slaughtered for human consumption within 4 days of the last treatment. Milk that has been taken during treatment and for 36 hours after the last treatment must not be used for food. Not for use in dry dairy cows. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal. Not for use in horses intended for food.

Precautions – As a class, cyclooxygenase inhibitory NSAIDs may be associated with GI and renal toxicity. Sensitivity to drug-associated adverse effects varies with the individual patient. Patients at greatest risk for renal toxicity are those that are dehydrated, on concomitant diuretic therapy, or those with renal, cardiovascular and/or hepatic dysfunction. Since many NSAIDs possess the potential to induce GI ulceration, concomitant use of Flunixin meglumine injectable solution with other anti-inflammatory drugs, such as other NSAIDs and corticosteroids, should be avoided or closely monitored.
Horse: The effect of Flunixin meglumine injectable solution on pregnancy has not been determined.
Cattle: Do not use in bulls intended for breeding, as reproductive effects of Flunixin meglumine injectable solution in these classes of cattle have not been investigated. NSAIDs are known to have potential effects on both parturition and the estrous cycle. There may be a delay in the onset of estrus if Flunixin is administered during the prostaglandin phase of the estrous cycle. The effects of Flunixin on imminent parturition have not been evaluated in a controlled study. NSAIDs are known to have the potential to delay parturition through a tocolytic effect. Do not exceed the recommended dose.

Adverse Reactions (Side Effects) – In horses, isolated reports of local reactions following intramuscular injection, particularly in the neck, have been received. These include localized swelling, sweating, induration and stiffness. In rare instances in horses, fatal or nonfatal clostrial infections or other infections have been reported in association with intramuscular use of Flunixin meglumine injectable solution. In horses and cattle, rare instances of anaphylactic-like reactions, some of which have been fatal, have been reported, primarily following intravenous use.

Storage Conditions: Store between 36 – 86F.

Rev. 1/08

SmartPak™
40 Grissom Road, Suite 500
Plymouth, MA 02360
Phone: 1-800-431-4194
Fax: 1-800-431-4179
www.SmartPak.com